20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastrointestinal cancer Cell culture and mouse studies identified a quinazoline-based compound that could help treat c-Kit- and PDGFR-mutant gastrointestinal stromal tumors (GISTs). Chemical synthesis of phenoxyquinazoline- and quinolone-based PDGFRA inhibitors followed by testing in...
19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Peptides A fibrin matrix loaded with synthetic laminin peptides that bind growth factors could be used for wound healing and tissue regeneration applications. The peptides are 24- and 19-mer synthetic analogs of human laminin...
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma (RCC) could avoid nephrectomy without compromising survival. The data were presented at the American...
15:24 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Deciphera reports updated Phase I data for DCC-2618 in GIST

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase...